ARTICLE | Product Development
Merck KGaA’s bintrafusp alfa miss suggests there’s still more to learn about TGFβ
Phase III miss in NSCLC raises questions about the hypothesis that TGFβ can help overcome checkpoint resistance
January 21, 2021 2:03 AM UTC
The Phase III miss for Merck KGaA’s bintrafusp alfa in non-small cell lung cancer takes one of the most promising indications for the GSK-partnered program out of contention, and raises questions about the popular hypothesis that TGFβ can help overcome checkpoint resistance.
On Wednesday, Merck KGaA (Xetra:MRK) said it discontinued the Phase III INTR@PID Lung 037 study of bintrafusp alfa after an independent data monitoring committee said it was unlikely to meet its co-primary endpoint of progression-free survival. ...